HK1209339A1 - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations

Info

Publication number
HK1209339A1
HK1209339A1 HK15110095.6A HK15110095A HK1209339A1 HK 1209339 A1 HK1209339 A1 HK 1209339A1 HK 15110095 A HK15110095 A HK 15110095A HK 1209339 A1 HK1209339 A1 HK 1209339A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Application number
HK15110095.6A
Other languages
English (en)
Chinese (zh)
Inventor
Chris Beattie
Original Assignee
Morex Dev Partners Llp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morex Dev Partners Llp filed Critical Morex Dev Partners Llp
Publication of HK1209339A1 publication Critical patent/HK1209339A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK15110095.6A 2012-11-23 2015-10-15 Pharmaceutical formulations HK1209339A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1221125.6A GB201221125D0 (en) 2012-11-23 2012-11-23 Pharmaceutial formulations
PCT/EP2013/074490 WO2014079977A1 (en) 2012-11-23 2013-11-22 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
HK1209339A1 true HK1209339A1 (en) 2016-04-01

Family

ID=47560584

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110095.6A HK1209339A1 (en) 2012-11-23 2015-10-15 Pharmaceutical formulations

Country Status (20)

Country Link
US (1) US9358290B2 (ja)
EP (1) EP2922571B1 (ja)
JP (1) JP6279599B2 (ja)
KR (1) KR20150086283A (ja)
CN (1) CN104853777B (ja)
CA (1) CA2890271A1 (ja)
CY (1) CY1119713T1 (ja)
DK (1) DK2922571T3 (ja)
ES (1) ES2646010T3 (ja)
GB (1) GB201221125D0 (ja)
HK (1) HK1209339A1 (ja)
HR (1) HRP20171652T1 (ja)
HU (1) HUE035198T2 (ja)
LT (1) LT2922571T (ja)
NO (1) NO2922571T3 (ja)
PL (1) PL2922571T3 (ja)
PT (1) PT2922571T (ja)
RS (1) RS56499B1 (ja)
SI (1) SI2922571T1 (ja)
WO (1) WO2014079977A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201212409D0 (en) * 2012-07-12 2012-08-22 Morex Dev Partners Llp Cancer treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925736A (en) 1988-07-06 1990-05-15 Long Island Jewish Medical Center Topical hematoporphyrin
BR0214009A (pt) 2001-11-09 2004-11-03 Quadra Logic Tech Inc Método e composição para estimular o crescimento de pelos sobre a pele
US6995260B2 (en) * 2004-05-20 2006-02-07 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
US8287839B2 (en) * 2006-12-04 2012-10-16 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
US8444953B2 (en) * 2007-03-22 2013-05-21 Brookhaven Science Associates, Llc Symmetric and asymmetric halogen-containing metallocarboranylporphyrins and uses thereof
EP2194027A4 (en) * 2007-09-03 2011-04-27 Kawamura Inst Chem Res METHOD FOR PRODUCING A STRUCTURE COATED WITH A NANOSTRUCTURE COMPOSITE, A STRUCTURE COATED WITH A NANOSTRUCTURE COMPOUND AND A NANOSTRUCTURED COMPOSITE STRUCTURE REACTOR
GB0819594D0 (en) 2008-10-24 2008-12-03 Univ Coimbrra Process
GB201212409D0 (en) * 2012-07-12 2012-08-22 Morex Dev Partners Llp Cancer treatment

Also Published As

Publication number Publication date
SI2922571T1 (sl) 2017-12-29
NO2922571T3 (ja) 2018-02-03
US20150297717A1 (en) 2015-10-22
JP2016500090A (ja) 2016-01-07
HRP20171652T1 (hr) 2017-12-15
EP2922571B1 (en) 2017-09-06
DK2922571T3 (da) 2017-11-13
PL2922571T3 (pl) 2018-03-30
CY1119713T1 (el) 2018-06-27
WO2014079977A1 (en) 2014-05-30
ES2646010T3 (es) 2017-12-11
CN104853777A (zh) 2015-08-19
KR20150086283A (ko) 2015-07-27
LT2922571T (lt) 2017-11-10
US9358290B2 (en) 2016-06-07
PT2922571T (pt) 2017-11-07
RS56499B1 (sr) 2018-01-31
CN104853777B (zh) 2019-03-08
JP6279599B2 (ja) 2018-02-14
GB201221125D0 (en) 2013-01-09
CA2890271A1 (en) 2014-05-30
EP2922571A1 (en) 2015-09-30
HUE035198T2 (hu) 2018-05-02

Similar Documents

Publication Publication Date Title
HK1203812A1 (en) Novel pharmaceutical formulations
HK1209638A1 (en) Pharmaceutical compositions
HRP20181896T1 (hr) Farmaceutske formulacije
ZA201501930B (en) Pharmaceutical composition
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
HK1205146A1 (en) Pharmaceutical formulation
HK1205683A1 (en) Pharmaceutical formulation having improved stability
HK1215789A1 (zh) 藥物組合
ZA201502987B (en) Pharmaceutical composition
IL235988B (en) Drug composition is based on genotype or phenotype
EP2897590A4 (en) PHARMACEUTICAL COMPOSITION
GB201211153D0 (en) Pharmaceutical compositions
HK1209339A1 (en) Pharmaceutical formulations
HK1204945A1 (en) Pharmaceutical formulation containing flupirtin
EP2851078A4 (en) PHARMACEUTICAL COMPOSITION
GB201211403D0 (en) Pharmaceutical formulations
GB201211406D0 (en) Pharmaceutical formulations
IL238075A0 (en) pharmaceutical preparations
ZA201400751B (en) Pharmaceutical composition
GB201219234D0 (en) Pharmaceutical compositions
GB201111577D0 (en) Pharmaceutical formulations
GB201213303D0 (en) Pharmaceutical compositions
GB201204810D0 (en) Pharmaceutical compositions
GB201206178D0 (en) Formulations

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: ADDITION OF INVENTOR: RENNIE, JAMES - WADSWORTH, ANNE

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211125